Editorial: Pulmonary Hypertension: Mechanisms and Management, History and Future.
作者信息
Thompson A A Roger, Wilkins Martin R, Wild Jim M, Kiely David G, Lawrie Allan
机构信息
Department of Infection, Immunity and Cardiovascular Disease, The University of Sheffield, Sheffield, United Kingdom.
Sheffield Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.
出版信息
Front Med (Lausanne). 2020 Apr 21;7:125. doi: 10.3389/fmed.2020.00125. eCollection 2020.
Abstract
摘要
相似文献
1
Editorial: Pulmonary Hypertension: Mechanisms and Management, History and Future.社论：肺动脉高压：机制与管理、历史与未来
Front Med (Lausanne). 2020 Apr 21;7:125. doi: 10.3389/fmed.2020.00125. eCollection 2020.
2
The changing face of pulmonary hypertension diagnosis: a historical perspective on the influence of diagnostics and biomarkers.肺动脉高压诊断的变迁：诊断方法与生物标志物影响的历史视角
Pulm Circ. 2020 Feb 4;10(1):2045894019892801. doi: 10.1177/2045894019892801. eCollection 2020 Jan-Mar.
3
Association of Elevated Plasma Endothelin-1 Levels With Pulmonary Hypertension, Mortality, and Heart Failure in African American Individuals: The Jackson Heart Study.血浆内皮素-1 水平升高与非裔美国人肺动脉高压、死亡率和心力衰竭的关系：杰克逊心脏研究。
JAMA Cardiol. 2016 Jul 1;1(4):461-9. doi: 10.1001/jamacardio.2016.0962.
4
Editorial: Therapeutics in pulmonary arterial hypertension.社论：肺动脉高压的治疗方法
Front Cardiovasc Med. 2024 Aug 6;11:1463305. doi: 10.3389/fcvm.2024.1463305. eCollection 2024.
5
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Biomarkers in pulmonary arterial hypertension.沙特肺高血压诊断与治疗指南：肺动脉高压的生物标志物。
Ann Thorac Med. 2014 Jul;9(Suppl 1):S92-7. doi: 10.4103/1817-1737.134047.
6
Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction.代谢综合征通过 ROS-miR-193b-NFYA 依赖性下调可溶性鸟苷酸环化酶介导，并导致射血分数保留的心力衰竭中的运动诱导性肺动脉高压。
Circulation. 2021 Aug 24;144(8):615-637. doi: 10.1161/CIRCULATIONAHA.121.053889. Epub 2021 Jun 23.
7
Serum Biomarkers in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.结缔组织病相关肺动脉高压的血清生物标志物。
Int J Mol Sci. 2023 Feb 20;24(4):4178. doi: 10.3390/ijms24044178.
8
Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.肺动脉高压的今明日影像学及循环生物标志物。
Cell Mol Life Sci. 2012 Sep;69(17):2805-31. doi: 10.1007/s00018-012-0950-4. Epub 2012 Mar 25.
9
Pulmonary arterial hypertension.肺动脉高压
Orphanet J Rare Dis. 2013 Jul 6;8:97. doi: 10.1186/1750-1172-8-97.
10
Plasma tumour and metabolism related biomarkers AMBP, LPL and Glyoxalase I differentiate heart failure with preserved ejection fraction with pulmonary hypertension from pulmonary arterial hypertension.血浆肿瘤和代谢相关生物标志物 AMBP、LPL 和 Glyoxalase I 可区分射血分数保留的心力衰竭合并肺动脉高压与特发性肺动脉高压。
Int J Cardiol. 2021 Dec 15;345:68-76. doi: 10.1016/j.ijcard.2021.10.136. Epub 2021 Oct 25.
引用本文的文献
1
Intracellular Chloride Channels Regulate Endothelial Metabolic Reprogramming in Pulmonary Arterial Hypertension.细胞内氯离子通道调节肺动脉高压中的血管内皮代谢重编程。
Am J Respir Cell Mol Biol. 2023 Jan;68(1):103-115. doi: 10.1165/rcmb.2022-0111OC.
本文引用的文献
1
A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension.靶向护骨素的治疗性抗体可减轻严重的实验性肺动脉高压。
Nat Commun. 2019 Nov 15;10(1):5183. doi: 10.1038/s41467-019-13139-9.
2
A Systematic Review of 4D-Flow MRI Derived Mitral Regurgitation Quantification Methods.4D 血流磁共振成像衍生的二尖瓣反流定量方法的系统评价
Front Cardiovasc Med. 2019 Aug 2;6:103. doi: 10.3389/fcvm.2019.00103. eCollection 2019.
3
The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients.肺动脉高压患者体验：一项英国患者的大型横断面研究。
BMC Pulm Med. 2019 Mar 21;19(1):67. doi: 10.1186/s12890-019-0827-5.
4
Diagnosis of Pulmonary Hypertension with Cardiac MRI: Derivation and Validation of Regression Models.心脏 MRI 诊断肺动脉高压：回归模型的建立和验证。
Radiology. 2019 Jan;290(1):61-68. doi: 10.1148/radiol.2018180603. Epub 2018 Oct 23.
5
High levels of healthcare utilization prior to diagnosis in idiopathic pulmonary arterial hypertension support the feasibility of an early diagnosis algorithm: the SPHInX project.特发性肺动脉高压诊断前的高医疗利用率支持早期诊断算法的可行性：SPHInX项目。
Pulm Circ. 2018 Oct-Dec;8(4):2045894018798613. doi: 10.1177/2045894018798613.
6
Comparison of quantitative multiple-breath specific ventilation imaging using colocalized 2D oxygen-enhanced MRI and hyperpolarized He MRI.应用共定位二维氧增强 MRI 和极化 He MRI 进行定量多次呼吸特异性通气成像的比较。
J Appl Physiol (1985). 2018 Nov 1;125(5):1526-1535. doi: 10.1152/japplphysiol.00500.2017. Epub 2018 Aug 30.
7
The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension.患者选择对慢性血栓栓塞性肺动脉高压生存的影响。
Eur Respir J. 2018 Sep 16;52(3). doi: 10.1183/13993003.00589-2018. Print 2018 Sep.
8
Identification of rare sequence variation underlying heritable pulmonary arterial hypertension.遗传性肺动脉高压相关罕见序列变异的鉴定。
Nat Commun. 2018 Apr 12;9(1):1416. doi: 10.1038/s41467-018-03672-4.
9
Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension.肺动脉高压患者中性粒细胞与淋巴细胞比值的探索性分析。
BMC Pulm Med. 2017 Apr 26;17(1):72. doi: 10.1186/s12890-017-0407-5.
10
Magnetic Resonance Imaging in the Prognostic Evaluation of Patients with Pulmonary Arterial Hypertension.磁共振成像在肺动脉高压患者预后评估中的应用
Am J Respir Crit Care Med. 2017 Jul 15;196(2):228-239. doi: 10.1164/rccm.201611-2365OC.
Zotero 插件